Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qianhai Health HoldingsHKSE:00911 +14.29%39 Interest Coverage is 150.73 as of Dec. 2025, which is 1915% above its 10-year median of 7.48. GuruFocus rates HKSE:00911 with a GF Score™ of 39/100 and a GF Value™ of HK$0.22 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 681 Drug Manufacturers companies, Qianhai Health Holdings ranks better than 84.58% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Qianhai Health Holdings's
Operating Income
for the
six
months ended in Dec. 2025 was HK$2.3 Mil. Qianhai Health Holdings's Interest Expense for the
six
months ended in Dec. 2025 was HK$-0.0 Mil.
Qianhai Health Holdings's interest coverage for the quarter that ended in Dec. 2025 was 150.73.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Qianhai Health Holdings Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Qianhai Health Holdings's Interest Coverage or its related term are showing as below:
HKSE:00911'
s Interest Coverage Range Over the Past 10 Years
Min: 3.73 Med: 7.48 Max: 184.34
Current: 184.34
HKSE:00911's Interest Coverage is ranked better than 84.58% of 681
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs HKSE:00911: 184.34
Qianhai Health Holdings (HKSE:00911) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Qianhai Health Holdings Interest Coverage Related Terms
Qianhai Health Holdings Interest Coverage Historical Data
* Premium members only.
The historical data trend for Qianhai Health Holdings's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Qianhai Health Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qianhai Health Holdings Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Qianhai Health Holdings's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Qianhai Health Holdings's Interest Coverage falls into.
Qianhai Health Holdings Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qianhai Health Holdings (HKSE:00911) has a Interest Coverage of 150.73 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Qianhai Health Holdings and its competitors. This is 1915% above median its historical median of 7.48. Over the past decade, Qianhai Health Holdings' Interest Coverage has ranged from 3.73 to 184.34. According to the industry distribution chart, Qianhai Health Holdings ranks #105 out of 681 companies in the Drug Manufacturers industry, placing it in the top 15.4%.
Is Qianhai Health Holdings' Interest Coverage too high?
Qianhai Health Holdings' current Interest Coverage of 150.73 is 1915% above median its 10-year median of 7.48. Over the past 10 years, this metric has ranged from a low of 3.73 to a high of 184.34. The Drug Manufacturers industry median Interest Coverage is 12.78. Qianhai Health Holdings' value of 150.73 is 1079.4% above this industry median. Based on the distribution chart, Qianhai Health Holdings ranks #105 out of 681 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Qianhai Health Holdings has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qianhai Health Holdings' Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Qianhai Health Holdings ranks #105 out of 681 companies for Interest Coverage. This places Qianhai Health Holdings in the top 15% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.78. Qianhai Health Holdings' value of 150.73 is 1079.4% above this benchmark. Historically, Qianhai Health Holdings' own Interest Coverage has ranged from 3.73 to 184.34 over the past decade. While the company's 10-year median is 7.48 vs. the industry median of 12.78, Qianhai Health Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qianhai Health Holdings's current Interest Coverage of 150.73 is 1079.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Qianhai Health Holdings and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qianhai Health Holdings's current Interest Coverage is 150.73, which is 1915% above median its own 10-year median of 7.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qianhai Health Holdings stock overvalued right now?
Based on GuruFocus' analysis, Qianhai Health Holdings (HKSE:00911) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.22, compared to a current price of HK$0.60 — trading 172.7% above its estimated fair value. The current Interest Coverage is 150.73, which is 1915% above median its 10-year median of 7.48 and 1079.4% above the Drug Manufacturers industry median of 12.78. Qianhai Health Holdings' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Qianhai Health Holdings (HKSE:00911), the current Interest Coverage is 150.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qianhai Health Holdings (HKSE:00911) Overvalued in 2026?
Based on GuruFocus' analysis, Qianhai Health Holdings stock appears to be overvalued.
The current stock price of HK$0.60 is trading 172.7% above its estimated GF Value™ of HK$0.22.
GuruFocus considers Qianhai Health Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:00911:
Interest Coverage: 150.73 (1915% above median its 10-year median of 7.48)
GF Value™: HK$0.22 vs. price of HK$0.60 (172.7% above fair value)
Industry Position: 1079.4% above the Drug Manufacturers median (#105 of 681)
No single metric tells the full story. See the HKSE:00911 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qianhai Health Holdings Ltd principally engaged in the sale of health products and electronic component products. It includes Chinese herbal medicines, skin-care and other healthcare products, and the sale of information technology components. The operating segments of the group are Healthcare products and Electronic component products. Healthcare products include the sale of healthcare products, including Chinese herbal medicines, skincare, and other healthcare products. Electronic component products include the sale of information technology components products including central processing units and semiconductors. The group's revenue is all derived from Hong Kong.
39GF Score
Get the complete analysis for HKSE:00911
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00911 has been successfully added to your 
